New clinical trials in CUP and a novel paradigm in cancer classification

Elie Rassy; Fabrice André

doi:10.1038/s41571-024-00942-7

New clinical trials in CUP and a novel paradigm in cancer classification

Elie Rassy, Fabrice André

Résultats de recherche: Contribution à un journal › !!Comment/debate

Résumé

Precision oncology has reached a milestone as data from two trials in which molecular profiling guided both site-specific and tumour-agnostic therapies indicate improved survival outcomes in patients with cancer of unknown primary. These findings can also be extrapolated and support the use of tissue-agnostic approaches in general, and also suggest that the tissue of origin might have a role in the agnostic classification of cancers and their response to treatment.

langue originale	Anglais
Pages (de - à)	833-834
Nombre de pages	2
journal	Nature Reviews Clinical Oncology
Volume	21
Numéro de publication	12
Les DOIs	https://doi.org/10.1038/s41571-024-00942-7
état	Publié - 1 déc. 2024

Accès au document

10.1038/s41571-024-00942-7

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{3191f9c66fe64ed0bb0fd28cf9797145,

title = "New clinical trials in CUP and a novel paradigm in cancer classification",

abstract = "Precision oncology has reached a milestone as data from two trials in which molecular profiling guided both site-specific and tumour-agnostic therapies indicate improved survival outcomes in patients with cancer of unknown primary. These findings can also be extrapolated and support the use of tissue-agnostic approaches in general, and also suggest that the tissue of origin might have a role in the agnostic classification of cancers and their response to treatment.",

author = "Elie Rassy and Fabrice Andr{\'e}",

note = "Publisher Copyright: {\textcopyright} Springer Nature Limited 2024.",

year = "2024",

month = dec,

day = "1",

doi = "10.1038/s41571-024-00942-7",

language = "English",

volume = "21",

pages = "833--834",

journal = "Nature Reviews Clinical Oncology",

issn = "1759-4774",

number = "12",

}

TY - JOUR

T1 - New clinical trials in CUP and a novel paradigm in cancer classification

AU - Rassy, Elie

AU - André, Fabrice

N1 - Publisher Copyright: © Springer Nature Limited 2024.

PY - 2024/12/1

Y1 - 2024/12/1

N2 - Precision oncology has reached a milestone as data from two trials in which molecular profiling guided both site-specific and tumour-agnostic therapies indicate improved survival outcomes in patients with cancer of unknown primary. These findings can also be extrapolated and support the use of tissue-agnostic approaches in general, and also suggest that the tissue of origin might have a role in the agnostic classification of cancers and their response to treatment.

AB - Precision oncology has reached a milestone as data from two trials in which molecular profiling guided both site-specific and tumour-agnostic therapies indicate improved survival outcomes in patients with cancer of unknown primary. These findings can also be extrapolated and support the use of tissue-agnostic approaches in general, and also suggest that the tissue of origin might have a role in the agnostic classification of cancers and their response to treatment.

UR - http://www.scopus.com/inward/record.url?scp=85203529822&partnerID=8YFLogxK

U2 - 10.1038/s41571-024-00942-7

DO - 10.1038/s41571-024-00942-7

M3 - Comment/debate

AN - SCOPUS:85203529822

SN - 1759-4774

VL - 21

SP - 833

EP - 834

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

IS - 12

ER -